Mie Jareid1, Jean-Christophe Thalabard2, Morten Aarflot3, Hege M Bøvelstad4, Eiliv Lund5, Tonje Braaten6. 1. Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Electronic address: mie.jareid@uit.no. 2. Applied Mathematics Lab, UMR CNRS 8145, Paris Descartes University, USPC, Paris, France. Electronic address: Jean-Christophe.Thalabard@parisdescartes.fr. 3. Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Electronic address: morten.aarflot@uit.no. 4. Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Electronic address: hege.m.bovelstad@uit.no. 5. Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Electronic address: eiliv.lund@uit.no. 6. Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Electronic address: tonje.braaten@uit.no.
Abstract
OBJECTIVE: Women with ovarian cancer have poor survival rates, which have proven difficult to improve; therefore primary prevention is important. The levonorgestrel-releasing intrauterine system (LNG-IUS) prevents endometrial cancer, and recent studies suggested that it may also prevent ovarian cancer, but with a concurrent increased risk of breast cancer. We compared adjusted risks of ovarian, endometrial, and breast cancer in ever users and never users of LNG-IUS. METHODS: Our study cohort consisted of 104,318 women from the Norwegian Women and Cancer Study, 9144 of whom were ever users and 95,174 of whom were never users of LNG-IUS. Exposure information was taken from self-administered questionnaires, and cancer cases were identified through linkage to the Cancer Registry of Norway. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated with Poisson regression using robust error estimates. RESULTS: Median age at inclusion was 52years and mean follow-up time was 12.5 (standard deviation 3.7) years, for a total of 1,305,435 person-years. Among ever users of LNG-IUS there were 18 cases of epithelial ovarian cancer, 15 cases of endometrial cancer, and 297 cases of breast cancer. When ever users were compared to never users of LNG-IUS, the multivariable RR of ovarian, endometrial, and breast cancer was 0.53 (95% CI: 0.32, 0.88), 0.22 (0.13, 0.40), and 1.03 (0.91, 1.17), respectively. CONCLUSION: In this population-based prospective cohort study, ever users of LNG-IUS had a strongly reduced risk of ovarian and endometrial cancer compared to never users, with no increased risk of breast cancer.
OBJECTIVE:Women with ovarian cancer have poor survival rates, which have proven difficult to improve; therefore primary prevention is important. The levonorgestrel-releasing intrauterine system (LNG-IUS) prevents endometrial cancer, and recent studies suggested that it may also prevent ovarian cancer, but with a concurrent increased risk of breast cancer. We compared adjusted risks of ovarian, endometrial, and breast cancer in ever users and never users of LNG-IUS. METHODS: Our study cohort consisted of 104,318 women from the Norwegian Women and Cancer Study, 9144 of whom were ever users and 95,174 of whom were never users of LNG-IUS. Exposure information was taken from self-administered questionnaires, and cancer cases were identified through linkage to the Cancer Registry of Norway. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated with Poisson regression using robust error estimates. RESULTS: Median age at inclusion was 52years and mean follow-up time was 12.5 (standard deviation 3.7) years, for a total of 1,305,435 person-years. Among ever users of LNG-IUS there were 18 cases of epithelial ovarian cancer, 15 cases of endometrial cancer, and 297 cases of breast cancer. When ever users were compared to never users of LNG-IUS, the multivariable RR of ovarian, endometrial, and breast cancer was 0.53 (95% CI: 0.32, 0.88), 0.22 (0.13, 0.40), and 1.03 (0.91, 1.17), respectively. CONCLUSION: In this population-based prospective cohort study, ever users of LNG-IUS had a strongly reduced risk of ovarian and endometrial cancer compared to never users, with no increased risk of breast cancer.
Authors: Kay J Park; Vance Broach; Dennis S Chi; Irina Linkov; Frank Z Stanczyk; Prusha Patel; Anjali Jotwani; Celeste Leigh Pearce; Malcolm C Pike; Noah D Kauff Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: Omar L Nelson; Rebecca Rosales; Jane M Turbov; Larry G Thaete; J Mark Cline; Gustavo C Rodriguez Journal: Cancer Prev Res (Phila) Date: 2021-11-29
Authors: Jiaxi Yang; Naoko Sasamoto; Ana Babic; Allison F Vitonis; Mary K Townsend; Linda Titus; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry Journal: Int J Cancer Date: 2021-03-17 Impact factor: 7.316
Authors: Jung-Yoon Yoo; Hee-Bum Kang; Russell R Broaddus; John I Risinger; Kyung-Chul Choi; Tae Hoon Kim Journal: BMC Cancer Date: 2018-05-29 Impact factor: 4.430
Authors: Minh Tung Phung; Alice W Lee; Anna H Wu; Andrew Berchuck; Kathleen R Cho; Daniel W Cramer; Jennifer Anne Doherty; Marc T Goodman; Gillian E Hanley; Holly R Harris; Karen McLean; Francesmary Modugno; Kirsten B Moysich; Bhramar Mukherjee; Joellen M Schildkraut; Kathryn L Terry; Linda J Titus; Susan J Jordan; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02-22 Impact factor: 4.090